Carbapenems in the Multidisciplinary Hospital: Some Clinical and Economic Consequences

Clinical Microbiology and Antimicrobial Chemotherapy. 2014; 16(1):33-38

Type
Original Article

Abstract

The changes in carbapenem consumption during 6 consecutive years have been studied in retrospective trial. 88% of carbapenems have been administered in the ICU’s and hematology department. The 3-fold increase of the total consumption during observational period has been registered, mainly – due to meropenem generics. The association of generic consumption elevation with the more frequent detection of A. baumannii carbapenemresistant strains and the tendency for increased attributable mortality in the burn centre ICU have been observed.

Views
0 Abstract
0 PDF
0 Crossref citations
Shared